Clinical Trials Browser

Phase 2 × INDUSTRY × relmacabtagene autoleucel × Clear all

NCT06093841 2025-02-11

Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

Phase 2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06479356 2024-08-21

CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma

Phase 2 Recruiting

Lymphoma, Non-Hodgkin, Recurrence